The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by Cantor Fitzgerald on March 12, 2025. The analyst firm set a price target for $0.00 expecting BEAM to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by Cantor Fitzgerald, and Beam Therapeutics reiterated their overweight rating.

The last upgrade for Beam Therapeutics Inc happened on March 10, 2025 when Scotiabank raised their price target to $40. Scotiabank previously had a sector perform for Beam Therapeutics Inc.

The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $0.00 to $0.00. The current price Beam Therapeutics (BEAM) is trading at is $24.80, which is out of the analyst’s predicted range.